Conference Day Two - Thursday, December 5
8.05 Check-In & Coffee
8.55 Chair’s Opening Remarks
Plenary Session: Academic Pioneers
9.05 Therapeutic Gene Editing for Cardiovascular and Metabolic Diseases: From the Leading Cause of Death to N-Of-1 Disorders
9.35 Advancing the Development of Safe and Effective Cell & Gene Therapies Using INDUCE-seq®
10.05 Engineering and Evolution of Hyperactive, CRISPR-Associated Transposases (VIRTUAL)
10.35 Morning Refreshments
Innovation & Early Development Track
Translating to the Clinic Track
Progressing Epigenome Editors into the Clinic
Moderator: Luca Biasco, Nvelop Therapeutics
Outlining a Path to the Clinic
Moderator: Narin Ahmed, Tessera Therapeutics
11.20 Programmable Gene Activation, Silencing &
Multiplexing for Precise Gene Regulation
Shane Wright, Associate Scientist II, Chroma Medicine
11.20 Regulatory Strategies to Enable the Clinical Trial
Applications of Genome Editing Products
Claire Levée, Director, Regulatory Affairs, Genetics Medicines,
Regeneron Pharmaceuticals
11.50 Epigenome editing with CRIPSR-GNDM® as a treatment platform for unmet medical conditions
Tetsuya Yamagata, Chief Scientific Officer, Modalis Therapeutics
11.50 Editing HBG1/2 and BCL11A for Beta
Hemoglobinopathies
Sheryl Bowley, Director, HSC Therapies, Editas Medicinee
12.20 CRISPR Epigenetic Modification to Treat Hepatitis B
Britta Jones, Senior Scientist, Tune Therapeutics
12.20 Compact Nucleases: Outlining a Roadmap Towards
Clinical Evaluation
Mark DeWitt, Associate Director, Mammoth Biosciences
12.50 Lunch
Innovation & Early Development Track
Translating to the Clinic Track
Validating the Next Generation of Delivery Vehicles
Moderator: Luca Biasco, Nvelop Therapeutics
Driving Novel Nucleases Towards the Clinic
Moderator: Narin Ahmed, Tessera Therapeutics
1.50 In Vivo RNA Delivery to T Cells & Hematopoietic Stem
Cells in Humanized Mice & Non-Human Primates Using
Targeting Lipid Nanoparticles
Apiwat Wangweerawong, Director, Delivery Chemistry,
Tessera Therapeutics
1.50 AFNT-212: A Non-Viral Gene-Edited TCR-T Cell Therapy
Ankit Gupta, Senior Director, Head of Gene Editing, Affini-T Therapeutics
2.20 In Vivo Application of Exosome-Based Genome Editing
Technology
Dave Carter, Head of Research, Evox Therapeutics
2.20 Disruption of Aberrant Splicing by Gene Editing with
a Type V CRISPR-Cas Enzyme as a Potential Treatment for
ALS
Catherine Symonds, Senior Director, Head of Strategy & New
Product Planning, Arbor Biotechnologies